Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | GLA | P06280 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31078533 | 0.85 | KDM4E (0.66) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL3028074 | 0.85 | KDM4E (0.66) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL29416299 | 0.84 | KDM4E (0.70) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL68952 | 0.84 | KDM4E (0.70) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL30957166 | 0.81 | SIRT3 (0.61) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL9700938 | 0.81 | KDM4E (0.61) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL1440123 | 0.81 | SIRT3 (0.61) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL6640350 | 0.80 | CA12 (0.56) | KDM4EALDH1A1TSHRCA12CA1 | |
| SCHEMBL8123257 | 0.80 | EGFR (0.41) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL1062129 | 0.79 | ALDH1A1 (0.74) | KDM4EALDH1A1GAAGLALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-11597728-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-07 | — | — | US | disclosed |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| WO-2022155419-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2022-07-21 | — | — | WO | disclosed |
| EP-3856179-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2021-08-04 | — | — | EP | disclosed |
| US-9975904-B2 | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170183359-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-29 | — | — | US | disclosed |
| WO-2017088738-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | 南京明德新药研发股份有限公司 | 2017-06-01 | — | — | WO | disclosed |
| US-9630976-B2 | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20150232478-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-20 | — | — | US | disclosed |
| EP-2871179-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO Pharmaceutical Co., Ltd. (JP) | 2015-05-13 | — | — | EP | disclosed |
| EP-2552893-B1 | ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-20130096119-A1 | Isoquinolin-3-Ylurea Derivatives | BUR DANIEL (CH) | 2013-04-18 | — | — | US | disclosed |
| EP-2552893-A1 | ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011121555-A1 | ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183359-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | SSTR2, SSTR1, SSTR3 | KDM4E 4642/4885ALDH1A1 3249/4885GAA 927/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885ALDH1A1 344/4885GAA 139/4885 |
| US-20150232478-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | SSTR2, SSTR1, SSTR3 | KDM4E 4657/4885ALDH1A1 3156/4885GAA 847/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | KDM4E 4338/4885ALDH1A1 4236/4885GAA 27/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885ALDH1A1 344/4885GAA 139/4885 |
| US-11597728-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885ALDH1A1 344/4885GAA 139/4885 |
| US-20130096119-A1 | Isoquinolin-3-Ylurea Derivatives | CLIC1, IRF3, KCNH3 | KDM4E 3201/4885ALDH1A1 944/4885GAA 4352/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885ALDH1A1 344/4885GAA 139/4885 |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885ALDH1A1 344/4885GAA 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.